The Study of Tamoxifen and Raloxifene (STAR) is a clinical trial from the early 2000s designed determine how the drug raloxifene compares with the drug tamoxifen in reducing the incidence of breast cancer in women who are at increased risk of the disease.[1]

Research

One of the largest breast cancer prevention studies ever,[2] it included 22,000 women in 400 medical centers in the United States and Canada.[3][4][5]

The study concluded that raloxifene caused fewer side-effects and less endometrial cancer than tamoxifen.[6][7] Raloxifene was found to be more effective at preventing noninvasive breast cancer but less effective at preventing invasive breast cancer.[8]

References

  1. ↑ "Study of Tamoxifen and Raloxifene (STAR)". Weill Cornell Medical College.
  2. ↑ "Osteoporosis drug equals tamoxifen in preventing breast cancer", Pittsburgh Post-Gazette, April 18, 2006
  3. ↑ "Drug Slashes Breast Cancer Risk, Study Shows", New York Times, June 16, 1999
  4. ↑ Wickerham L. "What is the Study of Tamoxifen and Raloxifene Breast Cancer Prevention Trial?". ABC News.
  5. ↑ "Study of Tamoxifen and Raloxifene (STAR)". Columbia St. Mary's.
  6. ↑ "Teleconference: Study of Tamoxifen and Raloxifene (STAR) P-2". American Association for Cancer Research. 19 April 2010.
  7. ↑ "Raloxifene or tamoxifen: Which is the right drug for you?", USA Today, April 17, 2006
  8. ↑ "Raloxifene, Tamoxifen Both Guard Against Breast Cancer", Business Week, April 19, 2010


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.